Mavenclad vs. Aubagio

Reviewed on 12/11/2020

Are Mavenclad and Aubagio the Same Thing?

Mavenclad (cladribine) and Aubagio (teriflunomide) are used to treat relapsing forms of multiple sclerosis (MS).

Because of its safety profile, use of Mavenclad is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.

Mavenclad and Aubagio belong to different drug classes. Mavenclad is a purine antimetabolite and Aubagio is a pyrimidine synthesis inhibitor.

Side effects of Mavenclad and Aubagio that are similar include nausea.

Side effects of Mavenclad that are different from Aubagio include upper respiratory tract infection, headache, low white blood cell count (lymphopenia), back pain, joint pain, and insomnia.

Side effects of Aubagio that are different from Mavenclad include liver problems, influenza, hair loss or thinning hair, diarrhea, burning or prickly feeling in your skin, and numbness or tingling in your hands or feet that is different from your MS symptoms.

Both Mavenclad and Aubagio may interact with hormonal contraceptives.

Mavenclad may also interact with immunosuppressive drugs, hematotoxic drugs, antiviral and antiretroviral drugs, ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, reserpine, interferon-beta, corticosteroids, rifampicin, and St. John's wort.

Aubagio may also interact with warfarin.

What Are Possible Side Effects of Mavenclad?

Common side effects of Mavenclad include:

  • upper respiratory tract infection,
  • headache,
  • low white blood cell count (lymphopenia),
  • nausea,
  • back pain,
  • joint pain, and
  • insomnia

What Are Possible Side Effects of Aubagio?

Common side effects of Aubagio include:

  • liver problems,
  • influenza,
  • hair loss or thinning hair,
  • nausea,
  • diarrhea,
  • burning or prickly feeling in your skin, or
  • numbness or tingling in your hands or feet that is different from your MS symptoms.

Tell your doctor if you have serious side effects of Aubagio including:

  • fever,
  • chills,
  • body aches,
  • flu symptoms,
  • sores in your mouth and throat,
  • itching,
  • tired feeling,
  • loss of appetite,
  • dark urine,
  • clay-colored stools,
  • yellowing of the skin or eyes,
  • fast or racing heartbeats,
  • confusion,
  • little or no urinating,
  • chest pain,
  • dry cough,
  • wheezing,
  • feeling short of breath,
  • skin redness or peeling,
  • swelling,
  • rapid weight gain, or
  • severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.

QUESTION

What kind of disease is multiple sclerosis? See Answer

What Is Mavenclad?

Mavenclad (cladribine) is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of Mavenclad is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.

What Is Aubagio?

Aubagio (teriflunomide) is a pyrimidine synthesis inhibitor used to treat relapsing forms of multiple sclerosis (MS).

What Drugs Interact With Mavenclad?

Mavenclad may interact with immunosuppressive drugs, hematotoxic drugs, antiviral and antiretroviral drugs, ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, reserpine, interferon-beta, corticosteroids, rifampicin, St. John's wort, or hormonal contraceptives. Tell your doctor all medications and supplements you use. Mavenclad is not recommended for use during pregnancy; it may harm a fetus. Pregnancy should be excluded before the initiation of each treatment course of Mavenclad. Females of reproductive potential should prevent pregnancy by use of effective contraception during Mavenclad dosing and for at least 6 months after the last dose in each treatment course. Males of reproductive potential should take precautions to prevent pregnancy of their partner during Mavenclad dosing and for at least 6 months after the last dose in each treatment course. Because of the potential for serious adverse reactions in nursing infants, Mavenclad is not recommended for use while breastfeeding.

What Drugs Interact With Aubagio?

Aubagio may increase exposure of ethinyl estradiol and levonorgestrel. Patients taking Coumadin (warfarin) should be closely monitored as interactions may occur. Aubagio may cause major birth defects if used during pregnancy. Pregnancy must be excluded before starting treatment with Aubagio. Pregnancy must be avoided while taking Aubagio treat relapsing forms of multiple sclerosis (MS). If Aubagio is used during pregnancy, or if the patient becomes pregnant while taking Aubagio, the drug should be discontinued immediately and an accelerated elimination procedure should be initiated. Consult your doctor before breastfeeding.

How Should Mavenclad be Taken?

The cumulative dosage of 3.5 mg/kg Mavenclad is administered orally and divided into 2 treatment courses (1.75 mg/ kg per treatment course). Each treatment course is divided into 2 treatment cycles.

How Should Aubagio be Taken?

The recommended dose for Aubagio is 7 mg or 14 mg taken orally, once daily, with or without food.

SLIDESHOW

What Is Multiple Sclerosis? MS Symptoms, Causes, Diagnosis See Slideshow
Disclaimer

All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).

Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.

Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.

The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.

As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.

Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.

If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.

You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.

References
Serono. Mavenclad Product Information

www.mavenclad.com/?

Genzyme Corporation. Aubagio Product Information.

www.aubagio.com/?

Health Solutions From Our Sponsors